RVTY Quote, Financials, Valuation and Earnings

Azenta has a net margin of 12.98% compared to Revvity's net margin of -9.04%. Revvity's return on equity of 3.45% beat Azenta's return on equity of -7.97%.

Revvity has a consensus price target of $141.10, signalling upside risk potential of 26.17%. On the other hand Azenta has an analysts' consensus of $58.67 which suggests that it could grow by 55.86%. Given that Azenta has higher upside potential than Revvity, analysts believe Azenta is more attractive than Revvity.

Revvity has a beta of 1.064, which suggesting that the stock is 6.441% more volatile than S&P 500. In comparison Azenta has a beta of 1.521, suggesting its more volatile than the S&P 500 by 52.14%.

Revvity has a quarterly dividend of $0.07 per share corresponding to a yield of 0.25%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity pays 12.74% of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity quarterly revenues are $729.4M, which are larger than Azenta quarterly revenues of $147.5M. Revvity's net income of $94.6M is higher than Azenta's net income of -$13.3M. Notably, Revvity's price-to-earnings ratio is 50.64x while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity is 4.99x versus 2.91x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Rad Laboratories has a net margin of 12.98% compared to Revvity's net margin of -107.24%. Revvity's return on equity of 3.45% beat Bio-Rad Laboratories's return on equity of -23.87%.

Revvity has a consensus price target of $141.10, signalling upside risk potential of 26.17%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $372.83 which suggests that it could grow by 45.07%. Given that Bio-Rad Laboratories has higher upside potential than Revvity, analysts believe Bio-Rad Laboratories is more attractive than Revvity.

Revvity has a beta of 1.064, which suggesting that the stock is 6.441% more volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 0.984, suggesting its less volatile than the S&P 500 by 1.622%.

Revvity has a quarterly dividend of $0.07 per share corresponding to a yield of 0.25%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity pays 12.74% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity quarterly revenues are $729.4M, which are larger than Bio-Rad Laboratories quarterly revenues of $667.5M. Revvity's net income of $94.6M is higher than Bio-Rad Laboratories's net income of -$715.8M. Notably, Revvity's price-to-earnings ratio is 50.64x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity is 4.99x versus 2.83x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of 12.98% compared to Revvity's net margin of 1.4%. Revvity's return on equity of 3.45% beat Bruker's return on equity of 6.78%.

Revvity has a consensus price target of $141.10, signalling upside risk potential of 26.17%. On the other hand Bruker has an analysts' consensus of $68.42 which suggests that it could grow by 45.75%. Given that Bruker has higher upside potential than Revvity, analysts believe Bruker is more attractive than Revvity.

Revvity has a beta of 1.064, which suggesting that the stock is 6.441% more volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.406%.

Revvity has a quarterly dividend of $0.07 per share corresponding to a yield of 0.25%. Bruker offers a yield of 0.43% to investors and pays a quarterly dividend of $0.05 per share. Revvity pays 12.74% of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity quarterly revenues are $729.4M, which are smaller than Bruker quarterly revenues of $979.6M. Revvity's net income of $94.6M is higher than Bruker's net income of $13.7M. Notably, Revvity's price-to-earnings ratio is 50.64x while Bruker's PE ratio is 61.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity is 4.99x versus 2.08x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of 12.98% compared to Revvity's net margin of 0.07%. Revvity's return on equity of 3.45% beat Harvard Bioscience's return on equity of -18.36%.

Revvity has a consensus price target of $141.10, signalling upside risk potential of 26.17%. On the other hand Harvard Bioscience has an analysts' consensus of $4.25 which suggests that it could grow by 511.42%. Given that Harvard Bioscience has higher upside potential than Revvity, analysts believe Harvard Bioscience is more attractive than Revvity.

Revvity has a beta of 1.064, which suggesting that the stock is 6.441% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.371%.

Revvity has a quarterly dividend of $0.07 per share corresponding to a yield of 0.25%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity pays 12.74% of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity quarterly revenues are $729.4M, which are larger than Harvard Bioscience quarterly revenues of $24.6M. Revvity's net income of $94.6M is higher than Harvard Bioscience's net income of $18K. Notably, Revvity's price-to-earnings ratio is 50.64x while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity is 4.99x versus 0.32x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.